Focus: Vericel is a public biotechnology company focused on cellular therapy for regenerative medicine, with a diversified pipeline spanning orthopedic, cardiovascular, and vascular indications. The company generated $198M in revenue in FY 2025, positioning it as a mid-cap biotech with commercial traction.
Profile data last refreshed 13h ago · AI intelligence enriched 3w ago
Stable — net +3 jobs in 30d
9 added, 6 removed. Backfill posture.
Vericel offers a rare combination of commercial-stage products, late-stage pipeline catalysts, and public-company stability, making it attractive for professionals seeking regenerative medicine expertise with near-term value inflection; however, lack of headcount transparency and modest R&D investment may constrain senior research roles.
Help build intelligence for Vericel
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Vericel's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Vericel Corporation Estimates – NASDAQ:VCEL - TradingView
Vericel Corporation Estimates – NASDAQ:VCEL TradingView
Vericel to report Q3 2026 financial results on Nov 5 with live webcast and conference call. - Pluang
Vericel to report Q3 2026 financial results on Nov 5 with live webcast and conference call. Pluang
Vericel (VCEL), Why Is The Stock Back In The Spotlight? - Simply Wall Street
Vericel (VCEL), Why Is The Stock Back In The Spotlight? Simply Wall Street
VCEL: A Second Growth Engine Strengthens The Case For 2029 Margin Power - Simply Wall Street
VCEL: A Second Growth Engine Strengthens The Case For 2029 Margin Power Simply Wall Street
The Global Regenerative Medicine Market Size to Register - openPR.com
The Global Regenerative Medicine Market Size to Register openPR.com
Vericel (VCEL) Dropped, So What Is Driving Attention Now? - Simply Wall Street
Vericel (VCEL) Dropped, So What Is Driving Attention Now? Simply Wall Street
Showing 6 of 10 news items
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo